In a recent multi-centre study including patients with primary sclerosing cholangitis, cilofexor led to a reduction of alkaline phosphatase, ALT, AST and GGT as well as TIMP1 levels [28] and also improved patient-reported outcomes [29]. Here, TIMP1 is linked to sclerosing cholangitis.